Happy Thanksgiving! Save 50% on Your MarketBeat All Access Subscription.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
See how to make money instead of spending it on Black Friday with this offer (Ad)
Airbnb has a plan to fix cleaning fees
Saudi viewers angry over apparent ban on World Cup streaming
See how to make money instead of spending it on Black Friday with this offer (Ad)
Walmart shooting claims teen, young woman, father, mother
Cuba's informal market finds new space on growing internet
THE BEST BLACK FRIDAY DEAL YET (Ad)
Bird flu prompts slaughter of 1.8M chickens in Nebraska
US-England World Cup game seen by 19.98M on US television
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
See how to make money instead of spending it on Black Friday with this offer (Ad)
Airbnb has a plan to fix cleaning fees
Saudi viewers angry over apparent ban on World Cup streaming
See how to make money instead of spending it on Black Friday with this offer (Ad)
Walmart shooting claims teen, young woman, father, mother
Cuba's informal market finds new space on growing internet
THE BEST BLACK FRIDAY DEAL YET (Ad)
Bird flu prompts slaughter of 1.8M chickens in Nebraska
US-England World Cup game seen by 19.98M on US television
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
See how to make money instead of spending it on Black Friday with this offer (Ad)
Airbnb has a plan to fix cleaning fees
Saudi viewers angry over apparent ban on World Cup streaming
See how to make money instead of spending it on Black Friday with this offer (Ad)
Walmart shooting claims teen, young woman, father, mother
Cuba's informal market finds new space on growing internet
THE BEST BLACK FRIDAY DEAL YET (Ad)
Bird flu prompts slaughter of 1.8M chickens in Nebraska
US-England World Cup game seen by 19.98M on US television
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
See how to make money instead of spending it on Black Friday with this offer (Ad)
Airbnb has a plan to fix cleaning fees
Saudi viewers angry over apparent ban on World Cup streaming
See how to make money instead of spending it on Black Friday with this offer (Ad)
Walmart shooting claims teen, young woman, father, mother
Cuba's informal market finds new space on growing internet
THE BEST BLACK FRIDAY DEAL YET (Ad)
Bird flu prompts slaughter of 1.8M chickens in Nebraska
US-England World Cup game seen by 19.98M on US television
NASDAQ:ONCY

Oncolytics Biotech - ONCY Stock Forecast, Price & News

$1.57
+0.14 (+9.95%)
(As of 11/25/2022 08:58 PM ET)
Add
Compare
Today's Range
$1.44
$1.61
50-Day Range
$1.17
$1.96
52-Week Range
$0.80
$2.08
Volume
137,500 shs
Average Volume
188,072 shs
Market Capitalization
$92.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

Oncolytics Biotech MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
218.5% Upside
$5.00 Price Target
Short Interest
Healthy
0.19% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.89mentions of Oncolytics Biotech in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.29) to ($0.25) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.35 out of 5 stars

Medical Sector

272nd out of 1,044 stocks

Pharmaceutical Preparations Industry

124th out of 510 stocks

ONCY stock logo

About Oncolytics Biotech (NASDAQ:ONCY) Stock

Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Receive ONCY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oncolytics Biotech and its competitors with MarketBeat's FREE daily newsletter.

ONCY Stock News Headlines

Recap: Oncolytics Biotech Q3 Earnings
IIROC Trading Halt - ONC.WT
Oncolytics Biotech Q1 2022 Earnings Preview
Oncolytics Biotech GAAP EPS of -C$0.14
See More Headlines
Receive ONCY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oncolytics Biotech and its competitors with MarketBeat's FREE daily newsletter.

ONCY Company Calendar

Last Earnings
11/05/2021
Today
11/28/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/02/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ONCY
Employees
26
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.00
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+218.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-20,990,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.37 per share

Miscellaneous

Free Float
58,970,000
Market Cap
$92.68 million
Optionable
Not Optionable
Beta
2.06

Key Executives

  • Dr. Matthew C. Coffey M.B.A.
    Ph.D., Pres, CEO & Director
  • Mr. Kirk J. Look C.A.
    CA, Chief Financial Officer
  • Mr. Andrew R. de Guttadauro (Age 55)
    Global Head of Bus. Devel. & Pres of Oncolytics Biotech (U.S.) Inc
    Comp: $413.17k
  • Dr. Thomas C. Heineman M.D.
    Ph.D., Chief Medical Officer
  • Ms. Allison Hagerman P.Eng.
    P.M.P., VP of Product Devel.
  • Jon Patton
    Director of Investor Relations & Communication
  • Dr. Grey Wilkinson Ph.D.
    Scientist of Translational Medicine
  • Mr. John Mark Lievonen F.C.A.
    FCA, Consultant
  • Dr. Daniel Douglas Von Hoff F.A.C.P. (Age 74)
    FACP, M.D., Consultant













ONCY Stock - Frequently Asked Questions

Should I buy or sell Oncolytics Biotech stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oncolytics Biotech in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ONCY shares.
View ONCY analyst ratings
or view top-rated stocks.

What is Oncolytics Biotech's stock price forecast for 2023?

5 analysts have issued 1-year price targets for Oncolytics Biotech's stock. Their ONCY share price forecasts range from $3.00 to $6.00. On average, they predict the company's stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 218.5% from the stock's current price.
View analysts price targets for ONCY
or view top-rated stocks among Wall Street analysts.

How have ONCY shares performed in 2022?

Oncolytics Biotech's stock was trading at $1.39 at the beginning of the year. Since then, ONCY stock has increased by 12.9% and is now trading at $1.57.
View the best growth stocks for 2022 here
.

When is Oncolytics Biotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 2nd 2023.
View our ONCY earnings forecast
.

How were Oncolytics Biotech's earnings last quarter?

Oncolytics Biotech Inc. (NASDAQ:ONCY) announced its quarterly earnings data on Friday, November, 5th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.11) by $0.04. During the same quarter in the previous year, the company posted ($0.12) EPS.

What is Brad Thompson's approval rating as Oncolytics Biotech's CEO?

2 employees have rated Oncolytics Biotech Chief Executive Officer Brad Thompson on Glassdoor.com. Brad Thompson has an approval rating of 56% among the company's employees. This puts Brad Thompson in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Oncolytics Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oncolytics Biotech investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Gran Tierra Energy (GTE), Bionano Genomics (BNGO), KushCo (KSHB), OrganiGram (OGI), Pennsylvania Real Estate Investment Trust (PEI), CNBX Pharmaceuticals (CNBX), Zosano Pharma (ZSAN) and DHT (DHT).

What is Oncolytics Biotech's stock symbol?

Oncolytics Biotech trades on the NASDAQ under the ticker symbol "ONCY."

Who are Oncolytics Biotech's major shareholders?

Oncolytics Biotech's stock is owned by a number of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (0.04%).

How do I buy shares of Oncolytics Biotech?

Shares of ONCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Oncolytics Biotech's stock price today?

One share of ONCY stock can currently be purchased for approximately $1.57.

How much money does Oncolytics Biotech make?

Oncolytics Biotech (NASDAQ:ONCY) has a market capitalization of $92.68 million. The company earns $-20,990,000.00 in net income (profit) each year or ($0.33) on an earnings per share basis.

How can I contact Oncolytics Biotech?

Oncolytics Biotech's mailing address is 1167 Kensington Crescent Suite 210, Calgary A0, T2N 1X7. The official website for the company is www.oncolyticsbiotech.com. The company can be reached via phone at (403) 670-7377, via email at mmoore@oncolytics.ca, or via fax at 403-283-0858.

This page (NASDAQ:ONCY) was last updated on 11/28/2022 by MarketBeat.com Staff